Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
2022 · Clinical Microbiology and Infection · 100 citations
https://doi.org/10.1016/j.cmi.2021.12.026
M
Majid M. Alshamrani
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
1.2K
Citations
20
h-index
31
i10-index
Majid M. Alshamrani is an academic researcher from King Saud bin Abdulaziz University for Health Sciences. The author has contributed to research in topics: Antibiotic Use and Resistance & COVID-19 Clinical Research Studies & Nosocomial Infections in ICU. The author has an h-index of 20, co-authored 68 publications.
ORCID: 0000-0002-9961-8315Papers by this author
worksRisk of COVID-19 morbidity and mortality among healthcare workers working in a Large Tertiary Care Hospital
2021 · International Journal of Infectious Diseases · 53 citations
https://doi.org/10.1016/j.ijid.2021.07.009
Electronic Sepsis Screening Among Patients Admitted to Hospital Wards
2024 · JAMA · 26 citations
https://doi.org/10.1001/jama.2024.25982
High Burden of Resistant Gram Negative Pathogens Causing Device-associated Healthcare Infections in a Tertiary Care Setting in Saudi Arabia, 2008-2016
2020 · Journal of Global Antimicrobial Resistance · 25 citations
https://doi.org/10.1016/j.jgar.2020.07.013
Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
2021 · Infectious Diseases and Therapy · 20 citations
https://doi.org/10.1007/s40121-021-00496-6
Molecular Detection of Influenza A and B Viruses in Four Consecutive Influenza Seasons 2015–16 to 2018–19 in a Tertiary Center in Western Saudi Arabia
2021 · Journal of Epidemiology and Global Health · 20 citations
https://doi.org/10.2991/jegh.k.210427.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat